Blood pressure was measured as its own outcome
The SURMOUNT-1 blood-pressure analysis reported placebo-adjusted reductions of 6.8 mm Hg systolic and 4.2 mm Hg diastolic at 72 weeks with tirzepatide. These post hoc findings describe average differences in the studied obesity population, not a guaranteed change for every patient. They add information beyond body weight. Keep the baseline blood pressure, follow-up period and comparator attached to the result rather than treating the average reduction as a target for changing another prescribed medicine.[1]
Ambulatory measurements add another perspective
A SURMOUNT-1 substudy used 24-hour ambulatory monitoring. That differs from a single clinic reading because it samples blood pressure across daily activity and sleep. The study reported reductions with tirzepatide, but the measurement method is part of the finding. Do not compare an ambulatory average directly with a one-time reading without acknowledging that they represent different ways of observing blood pressure.[2]
A change from baseline is not always a treatment difference
Suppose a treatment group falls 8 units while a comparison group falls 3 units. The between-group difference is 5, not 8. This hypothetical example explains why a headline reporting only the change in the treated group can overstate the incremental effect. Check whether a published number is a within-group change, a placebo-adjusted difference or a percentage. Preserve the units as well as the comparison.
Weight change and blood pressure can move together
If two outcomes improve together, that does not by itself show which pathway caused the change. Analyses of possible mediation can help explore the relationship but rely on assumptions. Be cautious with claims that all benefit is independent of weight loss or that weight change explains everything. The reader should distinguish a measured effect from an explanation proposed for how it occurred. Related reading: how to interpret GLP-1 studies.
Do not stop blood-pressure medicine from a headline
An average trial reduction is not a personal instruction to discontinue antihypertensive treatment. Share readings and symptoms with the clinician responsible for blood-pressure care and ask how monitoring should fit with the new prescription. If separate clinics are involved, clarify who will review the information. A medication change requires an individualized decision, not a calculation based on the average participant.
Low pressure is a different concern
Zepbound labeling reports hypotension and notes its association with gastrointestinal events and dehydration. This is distinct from a favorable average reduction in a study. Report dizziness, fainting or other concerning symptoms promptly rather than assuming that lower must always mean better. The clinician can evaluate the actual circumstances and the full medicine list.[3] For a related question, see dehydration-related kidney warnings.
Make home records interpretable
Ask the care team how it wants blood pressure measured and recorded. Keep the measurement conditions and times consistent with those instructions, and note symptoms or relevant medicine changes. A page of unexplained numbers is harder to interpret than an organized record. Do not discard unusual readings solely because they differ from an expected trial average; ask how the team wants unexpected results handled.
Research should complement existing cardiovascular care
Blood-pressure findings are one part of the overall evidence. They should be considered alongside the condition being treated, adverse effects and established care needs. A provider comparison can clarify service access, but it does not determine which cardiovascular medicines remain necessary. Choose a follow-up arrangement that allows the relevant clinicians to coordinate rather than leaving each practice with only part of the history. Related reading: questions about coordinated care.
Continue your research
Sources & scope
Sources checked October 13, 2026. This guide explains published information and consumer research questions; it is not a clinical evaluation.
- SURMOUNT-1 blood-pressure analysis
- SURMOUNT-1 ambulatory blood-pressure substudy
- Zepbound prescribing information
Prices and terms can change. Confirm your specific offer directly with the provider.